HQ Team
March 17, 2023: Lupin Digital Health, a fully-owned subsidiary of Lupin, stated 83.3% of study patients with the acute coronary syndrome (ACS) maintained their vital signs in a programme aimed at valuing the efficacy of its Lyfe digital therapeutical platform.
The year-long study aimed to evaluate the efficacy of the company’s platform on cardiovascular events, re-hospitalisation, medication adherence, vital sign monitoring, and lifestyle changes among heart patients.
“During the 90-day interim analysis, patients enrolled in the program demonstrated significant improvement, with 90% adhering to the recommended medication, diet, and exercise regimen,” according to a company statement. It did not reveal the number of enrolled patients for the study.
“83.3% of patients maintained their vital signs within the normal range, and no re-hospitalisations” occurred during the first 30 days of enrolment.
The study results indicate that digital therapeutics programs will be crucial in patient care across the cardiology continuum powered by technology.
Remote patient care
The company stated that these results showcase a promising future for remote patient care in cardiology, utilising the potential of digital health to improve patients’ heart health.
Designed by leading Indian cardiologists, Lyfe helps patients improve their heart health through doctor-connected online and offline modules.
The FDA and CE-approved wearable devices record vital parameters and notify caregivers and doctors about off-range vitals and emergencies.
The Conformité Européene (CE) Mark is defined as the European Union’s mandatory conformity marking for regulating the goods sold within the European Economic Area since 1985. The CE marking represents a manufacturer’s declaration that products comply with the EU’s New Approach Directives.
Lyfe’s interface offers medication reminders and 24X7 emergency and ambulance assistance. In addition, Lyfe offers expert intervention in the form of dedicated care managers, health coaches and nutritionists.
30 cities, 70 towns
Lyfe plans to be present in 30 cities and 70 nearby towns in 2023, covering 75% of the cardiologists. It currently has more than 300 cardiologists on the platform.
“As an interventional cardiologist, I am happy to see such positive and promising early results of the study, with more than 90% of patients adhering to the recommended medication, diet, and exercise regimen prescribed by us,” said Dr Abhijeet Palshikar, an interventional cardiologist from Pune.
“By leveraging evidence-based technologies like digital therapeutics, we are revolutionising how we deliver healthcare to our patients.
“While this is an excellent start, we intend to undertake extensive clinical studies and foster collaborative efforts among all healthcare stakeholders to establish digital therapeutics in cardiology and unlock their full potential,” he said.
Sidharth Srinivasan, CEO of Lupin Digital Health, said the study’s outcomes showcase the effectiveness of “our evidence-based” and comprehensive heart care program in ensuring high adherence and low patient re-hospitalisation.
300 cardiologists
“It’s gratifying to see that more than 300 leading cardiologists have already enrolled in our Lyfe platform, and we are confident that this number will multiply.
“We are dedicated to optimising the patient experience through enhancing doctor-patient collaboration, continuously monitoring health vitals, increasing patient awareness, and improving therapy adherence, all leading to better outcomes,” he said.
The number of deaths due to heart attacks in India has remained consistently over 25,000 in the last four years and over 28,000 in the previous three years, according to data on Accidental Deaths & Suicides in India compiled by the National Crime Records Bureau.
